Medical Devices - Neurovascular & Cardiovascular Interventions
Strategic Profile
Penumbra is described as the world's leading thrombectomy company, with a portfolio focused on computer assisted vacuum thrombectomy (CAVT™) and related devices for serious vascular and neurovascular conditions. Boston Scientific has agreed to buy Penumbra for about $15 billion in cash and stock in a deal that bolsters its cardiovascular portfolio.
Cyborg Score Rationale
Penumbra's 2024 revenue was $1.19 billion, an increase of 12.86% compared to the previous year. Q4 2025 revenue is estimated at $383.0M–$384.8M with full-year revenue estimated at $1,401.3M–$1,403.1M. The company maintains strong market positioning despite a pending acquisition.
Top Insights
Q4 2025 revenue grew 21-22% YoY, with organic ex-China growth of 23-24%
Boston Scientific acquisition valued at ~$15 billion represents major strategic exit for shareholders
Gross margins maintained at 67-68%, demonstrating pricing power and operational efficiency
Penumbra System was the first FDA-cleared aspiration-based mechanical thrombectomy device, establishing market leadership in neurovascular intervention
Named Competitors
Boston Scientific — Leading cardiovascular and medical device company acquiring Penumbra
Stryker — Medical device manufacturer with neurovascular portfolio
Recent Developments
(January 2026) Boston Scientific announced acquisition of Penumbra for $374 per share in cash and stock
(November 2025) Q3 2025 earnings reported with strong revenue and margin performance